I thought this drug deserved a little more attention.
www.sciencedirect.com
The administration of apomorphine and piribedil, two dopaminergic agents, significantly reduced thyrotropin (TSH) and prolactin levels in six female patients with primary hypothyroidism. These data provide further evidence for an inhibitory role of dopaminergic stimulation on TSH secretion.
pubmed.ncbi.nlm.nih.gov
In baboons, the intravenous administration of piribedil, a dopaminergic agonist, was associated with marked dose dependent increases in CBF and cerebral oxygen consumption. We have studied the effects of piribedil on CBF in 20 normal, human volunteers of comparable ages. Ten received 0.1 mg/kg piribedil intravenously for 30 min; the other ten received 0.2 mg/kg. In the first group, CBF did not vary significantly, in the second group, there was a mean increase in CBF of 21.8% (p less than or equal to 0.005). In man, as in animals, piribedil provokes an increase of CBF.
agris.fao.org
in addition to its well-known antiparkinsonian properties, piribedil may also have antidementic, pro-cognitive (nootropic), anti-amnestic, antidepressant, anxiolytic, analgesic, and vasodilating properties. The vasodilating effect of piribedil is most evident in small cerebral vessels. Piribedil also can reduce the secretion of prolactin and several other stress hormones.
Rather interesting I thought. An interesting addition to the arsenal of pro-dopaminergics or a dangerous pharmaceutical? @haidut @yerrag
Effect of apomorphine and piribedil on the secretion of thyrotropin and prolactin in patients with primary hypothyroidism
The administration of apomorphine and piribedil, two dopaminergic agents, significantly reduced thyrotropin (TSH) and prolactin levels in six female p…
The administration of apomorphine and piribedil, two dopaminergic agents, significantly reduced thyrotropin (TSH) and prolactin levels in six female patients with primary hypothyroidism. These data provide further evidence for an inhibitory role of dopaminergic stimulation on TSH secretion.
Effects of a dopaminergic agonist (piribedil) on cerebral blood flow in man - PubMed
In baboons, the intravenous administration of piribedil, a dopaminergic agonist, was associated with marked dose dependent increases in CBF and cerebral oxygen consumption. We have studied the effects of piribedil on CBF in 20 normal, human volunteers of comparable ages. Ten received 0.1 mg/kg...
pubmed.ncbi.nlm.nih.gov
In baboons, the intravenous administration of piribedil, a dopaminergic agonist, was associated with marked dose dependent increases in CBF and cerebral oxygen consumption. We have studied the effects of piribedil on CBF in 20 normal, human volunteers of comparable ages. Ten received 0.1 mg/kg piribedil intravenously for 30 min; the other ten received 0.2 mg/kg. In the first group, CBF did not vary significantly, in the second group, there was a mean increase in CBF of 21.8% (p less than or equal to 0.005). In man, as in animals, piribedil provokes an increase of CBF.
PIRIBEDIL: INDICATIONS FOR ITS USE IN PSYCHIATRY AND ADDICTION MEDICINE
AGRICULTURAL SCIENCE AND TECHNOLOGY INFORMATION
agris.fao.org
in addition to its well-known antiparkinsonian properties, piribedil may also have antidementic, pro-cognitive (nootropic), anti-amnestic, antidepressant, anxiolytic, analgesic, and vasodilating properties. The vasodilating effect of piribedil is most evident in small cerebral vessels. Piribedil also can reduce the secretion of prolactin and several other stress hormones.
Rather interesting I thought. An interesting addition to the arsenal of pro-dopaminergics or a dangerous pharmaceutical? @haidut @yerrag
